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Patient samples are routinely typed for ABO prior to transfusion. 
Determining the ABO group requires both red blood cell (RBC) 
antigen typing for A and B (forward type) and testing for anti-A 
and anti-B in the plasma (reverse type). An ABO discrepancy 
exists when the result of an ABO RBC typing, or forward 
type, does not agree with the result of the plasma typing, or 
reverse type. This brief review examines several causes of ABO 
discrepancies encountered in the clinical transfusion service. 
Options for resolving these discrepancies are presented, including 
a discussion of which discrepancies should be resolved using 
molecular testing. Finally, case studies illustrate transfusion 
options in patients with ABO discrepancies. Discrepancies can 
also be encountered when ABO typing is performed on samples 
from blood or tissue donors, although those discrepancies 
will not be discussed in this review. Immunohematology 
2017;33:76–81.
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The ABO blood group system was first described in 1900 
by Landsteiner when agglutination was noted after mixing red 
blood cells (RBCs) and sera together from several individuals.1 
Landsteiner initially named the groups “A,” “B,” and “C” based 
on the RBC agglutination patterns. Terminology was later 
changed and group “C” became group “O,” which is more 
familiar to clinical laboratory scientists. Group AB, the fourth 
and final blood group of the system, was reported by von 
Decastello and Sturli in 1902.2
Their findings summarize the most important feature of 
the ABO blood group system: an ABO antibody (anti-A and/or 
anti-B) is almost always present in an individual’s plasma 
when the corresponding antigen(s) is absent from their RBCs.2 
This “double check” in determining an individual’s ABO group 
provides the ability to obtain a forward ABO type (patient 
RBCs typed using commercial antisera) and compare it with 
the reverse ABO type (patient plasma typed using commercial 
RBCs) (Table 1). The forward and reverse typing results should 
agree. An ABO discrepancy exists if they do not. Clinically, one 
should consider the potential for a worst-case scenario adverse 
event when transfusion is requested for a patient with an ABO 
discrepancy.
The purpose of this brief review is to examine several 
causes of ABO discrepancies encountered in the clinical 
transfusion service. Options for resolving these discrepancies 
will be presented, including a discussion of which discrepancies 
should be resolved using molecular testing. Finally, case studies 
are provided to illustrate transfusion options in patients with 
ABO discrepancies. Discrepancies can also be encountered 
when ABO typing is performed on samples from blood or 
tissue donors, but those discrepancies will not be discussed.
ABO Discrepancy Resolution: General Approach
An ABO discrepancy exists when the result of an ABO 
RBC typing, or forward type, does not agree with the result of 
the plasma typing, or reverse type. It is extremely important in 
the clinical laboratory to record these initial discrepant results. 
The following list summarizes a general approach that can be 
followed when an ABO discrepancy is encountered:
1. Repeat the test with the same sample.
2. Repeat the test with a new sample.
3. Review the patient’s medical record.
4. Review prior in-house laboratory testing records.
5. Contact other healthcare facilities.
6. Verify reagent and equipment performance.
Repeat the test from the beginning using the same sample 
because plasma and/or RBC suspensions can be inadvertently 
mixed up within the laboratory.3 Results and interpretations 
may also be mistakenly recorded. When repeating the testing, 
prepare a fresh RBC suspension, since a mix-up in sample 
identification may have occurred during initial testing. Most 
laboratories perform initial forward typing using normal 
saline–washed RBCs. Use normal saline–washed RBCs if 
initial typing was performed using plasma-suspended RBCs. 
If the repeat results are the same as the first, request a new 
sample for testing.
Table 1. Expected testing results of ABO blood groups
Patient RBCs and Patient plasma and
Patient blood group Anti-A Anti-B A1 RBCs B RBCs
O – – + +
A + – – +
B – + + –
AB + + – –
RBCs = red blood cells.
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Review prior in-house laboratory records for ABO typing 
results. Were similar discrepant results noted during previous 
testing? Many patients receive testing and transfusion in 
other facilities. Test results and transfusion records obtained 
at one facility may not be transferred between healthcare 
facilities. This “record fragmentation” can pose a problem 
in understanding discrepant results and planning for future 
transfusions.4 Contact prior facilities to inquire about prior 
test results and transfusion records. Review the patient’s 
medical record for clues to a potential cause in the discrepant 
results. For example, is the medical condition a potential 
cause (e.g., hematologic malignancy, post–stem cell transplant 
status) or has a medication or blood component recently been 
administered (e.g., intravenous immunoglobulin [IVIG] or 
group O apheresis platelets to a group A individual)?
ABO Discrepancies: Causes and Resolutions
Technical Problems
Technical problems should be ruled out with a check of 
reagents and equipment and repeating the testing. Examples 
of technical problems include a failure to follow standard 
operating procedure or commercial package inserts, improper 
centrifugation, improper preparation of RBC suspensions, 
or lack of addition of reagents. Appropriate medical and 
supervisory staff should be notified if technical problems are 
suspected, especially sample misidentification (see Discussion).
If technical problems are ruled out, one should then 
consider an intrinsic problem with either the RBCs 
and/or plasma as the cause of the discrepancy.5 For the sake 
of convenience and ease of resolution, discrepancies can be 
categorized as to whether the unexpected results occur in 
the forward or reverse typing (Fig. 1). The following sections 
provide further details regarding investigating and resolving 
forward (RBC) and reverse (plasma) discrepancies.
Red Blood Cell Discrepancy: Weak or Missing 
Reactivity
Forward ABO typing is performed using commercial 
antisera combined with patient RBCs, and this testing typically 
results in strong RBC agglutination. One should consider 
a potential ABO discrepancy when weaker than expected 
RBC agglutination is obtained (Table 2). Possible causes for 
weak or missing RBC reactivity include the following: A or 
B subgroups, recent transfusion, stem cell transplant, and 
leukemia or malignancy.
Note that in the RBC weak/missing reactivity example 
provided in Table 2, less than 3+ agglutination is obtained 
when patient RBCs are typed with anti-A. This finding may 
be seen in individuals with A subgroups. More frequently, 
individuals with A subgroups (or AsubgroupB) are detected 
because of a plasma discrepancy when anti-A1 is detected (see 
Plasma Discrepancy: Extra Plasma Reactivity). The variation 
in agglutination reactivity occurs because of differences 
in amounts of antigen present on RBCs or in secretions.5 
Subgroups of A are more common than subgroups of B. 
The two most important subgroups clinically are A1 and A2. 
A1 is distinguished by its reactivity with the lectin, Dolichos 
biflorus (anti-A1–like reactivity). For the sake of simplicity in 
this review, all other A subgroups nonreactive with Dolichos 
biflorus are referred to as “A2.” In addition, subgroup A2 shows 
increased reactivity with lectin, Ulex europaeus (anti-H–like 
reactivity). Subgroup A1 is nonreactive with Ulex europaeus.
Other methods are available that may prove of assistance 
in resolving discrepancies due to weak or missing RBC 
reactivity.6–9 Refer to the references and manufacturer’s 
directions for additional information. For example, forward 
ABO typing can be repeated using other monoclonal antisera, 
by increasing the incubation time, or by using enzyme-treated 
RBCs. Saliva studies can be performed to look for the presence 
of ABH antigens using inhibition methods because ABH 
antigens that are undetectable on the RBC surface may be 
detectable in the saliva of secretors. Molecular testing is also 
Table 2. Examples of ABO discrepancies
Patient RBCs and Patient plasma and
Anti-A Anti-B A1 RBCs B RBCs
RBC weak/missing reactivity 2+ 0 0–2+ 4+
RBC extra reactivity 2+ 3+ 3+ 0
RBC mixed-field reactivity 3+mf 0 0 4+
Plasma weak/missing reactivity 0 0 1+ 2+
Plasma extra reactivity 0 4+ 4+ 1+













Fig. 1 ABO grouping discrepancy categories
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available to identify an individual’s ABO genotype. However, 
molecular testing is seldom necessary for clinical use in 
resolving most common ABO discrepancies, and care must 
be taken to understand the potential for genotype/phenotype 
discrepancies5,10 (see Discussion).
Red Blood Cell Discrepancy: Extra RBC Reactivity
This discrepancy appears when unexpected or “extra” 
reactivity is detected in the forward typing. In the example 
provided in Table 2, the patient’s blood group likely would 
be interpreted as group B except that there is 2+ unexpected 
or “extra” reactivity with the patient’s RBCs and anti-A in 
the forward type. Possible causes of an ABO discrepancy 
due to extra RBC reactivity include a recent out-of-group 
transfusion, stem cell transplantation, rouleaux, an antibody 
to a reagent constituent, acquired B, and cold or warm 
autoantibodies.
When an ABO discrepancy due to extra RBC reactivity 
is suspected, check the patient’s medical record or speak 
with the patient or his or her clinician to determine if a recent 
transfusion or stem cell transplant has occurred. Recent 
transfusion with non–ABO-identical RBCs should result in 
a mixed-field typing result (see Red Blood Cell Discrepancy: 
Mixed-Field Reactivity), although interpretation may be 
difficult. Similar results may be noted post-transplant with 
non–ABO-identical stem cells. Rouleaux or an antibody to the 
reagent as a cause of extra RBC reactivity will likely only be 
seen if the patient’s RBCs are suspended in plasma prior to 
performing the forward type. In this situation, the discrepancy 
can be resolved by washing and re-suspending patient RBCs 
in saline, followed by repeat forward typing with anti-A and 
anti-B. Acquired B is a rare event. Patients not only must 
inherit or acquire this condition, but antisera must detect 
these RBC membrane modifications. Methods are available to 
remove cold and warm autoantibodies from RBCs.5,11 Follow 
the manufacturer’s directions if a commercial kit is used.
Red Blood Cell Discrepancy: Mixed-Field Reactivity
A RBC typing result that appears to contain RBCs from 
more than one ABO group is known as a “mixed-field reaction.” 
Using a gel method, unagglutinated RBCs appear at the 
bottom of the column, while agglutinated RBCs are detected 
at the top of the column. In Table 2, mixed-field reactivity was 
noted when the patient’s RBCs were typed with anti-A, and the 
results could be interpreted as either group A or group O. The 
reverse typing is consistent with group A. Possible causes of 
an ABO discrepancy due to mixed-field RBC reactivity include 
recent out-of-group transfusion, stem cell transplantation, A 
subgroup (especially A3 subgroup), fetomaternal hemorrhage, 
and chimerism.
Check the patient’s medical record or speak with the patient 
or the patient’s clinician to determine if a recent out-of-group 
transfusion or stem cell transplant has occurred. If a large 
fetomaternal hemorrhage is the suspected cause of the mixed-
field reactivity, a medical record review of the mother and 
newborn can also be of assistance. If mixed-field reactivity is 
uncertain, examine the RBC sample for the presence of mixed-
field reactivity in other blood group antigens when typed using 
serologic methods. Cell separation methods may be useful 
to permit patient phenotyping when recent transfusion has 
occurred (reticulocyte separation method12) or via hypotonic 
lysis for patients with sickle cell disease who have recently 
been transfused.13
Plasma Discrepancy: Weak or Missing Reactivity
Reverse ABO typing uses commercial RBCs combined 
with patient plasma. The agglutination observed from patient 
anti-A and anti-B may not consistently be as strong as that 
seen when using commercial antisera to type the patient RBCs 
in the forward ABO procedure. Thus, a reverse ABO typing 
method, such as tube, microplate, or column agglutination, 
should be selected that will adequately detect plasma anti-A 
and anti-B.5 Weak agglutination results should cause one to 
consider a potential ABO discrepancy prior to interpreting 
an ABO group (Table 2). Possible causes of weak or missing 
plasma reactivity include immunosuppression, post–stem cell 
transplantation, hypogammaglobulinemia, and age-related 
changes in ABO isoagglutinin levels.
A medical record review may assist in the initial 
evaluation of this discrepancy. Note the age of the patient. 
ABO isoagglutinins are usually initially detected around age 
3 months and reach adult levels between age 5 and 10 years. 
Antibody titers vary considerably between individuals and 
decline with age.14 Note the patient’s diagnosis and treatment 
plan. Consider the possibility of hypogammaglobulinemia 
caused either by an inherited immune disorder or secondary to 
another medical condition or medication (such as rituximab). 
Cold temperature incubation may be used to enhance detection 
of weak ABO antibodies, provided appropriate controls to 
detect cold autoantibodies and alloantibodies are included.6
Plasma Discrepancy: Extra Plasma Reactivity
Analogous to discrepancies secondary to extra RBC 
reactivity, these plasma discrepancies appear when 
unexpected or “extra” reactivity is detected in the reverse 
typing. In the example provided (Table 2), the patient’s blood 
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group likely would be interpreted as group B except that there 
is 1+ unexpected or extra reactivity with the patient’s plasma 
and the reagent B cells in the reverse type. Possible causes of 
an ABO discrepancy due to extra plasma reactivity include 
ABO subgroup, cold reactive alloantibody, cold reactive 
autoantibody, antibody to reagent constituent, transfusion 
of non-ABO-group–specific plasma components, infusion of 
IVIG, and post–stem cell transplant status.
A medical record review, speaking with the patient’s 
clinical team, or speaking with the patient may assist in the 
initial evaluation of this discrepancy. Has the patient received 
a component or derivative that could provide information to 
explain the extra plasma reactivity? For example, were non–
group-specific plasma-containing components transfused? 
Were derivatives infused? Has the patient ever been diagnosed 
with leukemia or any type of malignancy? Has the patient 
received a transplant, and if so, what type (stem cell or solid 
organ), and what was the donor’s blood group?
Because forward RBC typing is performed using 
commercial typing antisera, ABO subgroups are frequently 
recognized because of a discrepancy between RBC forward 
and plasma reverse typing results. Anti-A1 in A2 individuals 
is a common discrepancy that can occur in 1–8 percent of 
group A2 and 22–35 percent of group A2B individuals. The 
strength of reactivity between the anti-A1 with the A1 reagent 
RBCs is usually weaker than that noted between anti-B and 
B reagent RBCs. Additional room temperature tests can be 
performed to assist in resolving this discrepancy.15 In general, 
the following testing is generally sufficient to identify most 
group A subgroups with anti-A1:
• RBCs tested with anti-A1 lectin = negative
• Plasma tested with A2 and O RBCs = negative
• Plasma tested with A1 RBCs = positive
Unexpected anti-B can also occur in B subgroups, such as 
Bx. These subgroups are not as common as A subgroups. Note 
that it is not important to identify or categorize the subgroup 
for clinical management.5
Summary
The information from this section and test results should 
provide clues as to the source of the extraneous plasma 
reactivity. Causes other than ABO antibodies should be 
identified if testing with the A2, O, and/or autologous RBCs 
is positive.16 A positive antibody detection test at room 
temperature may be caused by a cold autoantibody (anti-I, 
anti-IH, etc.), cold alloantibody (anti-M, -N, -Lea, -P1, etc.), 
or an antibody to a reagent constituent. An antibody to a 
reagent constituent can be concluded if negative results are 
obtained using washed panel and reverse grouping cells. If a 
RBC alloantibody is identified, repeat the reverse ABO testing 
using antigen-negative reverse RBCs. If a RBC autoantibody is 
identified, repeat the reverse typing using cold auto-adsorbed 
plasma, if possible.5 Rabbit erythrocyte stroma–adsorbed 
plasma should not be used to determine reverse ABO group 
as anti-B, in addition to other RBC alloantibodies, can be 
removed during the adsorption process.17
Case Studies
Patient 1 and Patient 2
Two patients (patient 1 and patient 2) presented on the 
same day for preoperative evaluation. Both patients’ ABO 
testing results were identical (Table 3). The forward typing 
results were consistent with group A, but the reverse typing 
results appeared to demonstrate extra plasma reactivity with 
the A1 reagent RBCs. Plasma reactivity with the A1 RBCs was 
suspected to be extraneous, since it is weaker than would be 
expected in a group O individual; thus, the ABO group was 
not believed to be group A, and a discrepancy was investigated 
noting extra plasma reactivity between reagent A1 RBCs and 
patient plasma.
The tests were repeated to rule out technical issues, and 
identical results were obtained. A review of the medical records 
for both patients provided no significant information. Both 
patients were male and scheduled for elective joint replace-
ment surgery. Current medications included atorvastatin, 
hydrochlorothiazide, enalapril, and metoprolol. Neither patient 
had a history of prior transfusions, infusion of IVIG, or stem 
cell transplant.
Because extraneous plasma reactivity was suspected, both 
patients’ RBCs were initially tested with Dolichos biflorus, and 
their plasma was tested at room temperature against group O 
reagent screening RBCs, autologous RBCs, group A1 and group 
A2 RBCs for the presence of anti-A1, and for cold-reactive 
alloantibodies and autoantibodies.15
The RBCs of patient 1 demonstrated no agglutination 
with Dolichos biflorus. The plasma of patient 1 agglutinated 
two examples of A1 RBCs but did not agglutinate two examples 
of A2 RBCs. No agglutination was observed with the group 
Table 3. Initial test results, patients 1 and 2
Anti-A Anti-B Anti-A,B Anti-D Rh Control A1 RBCs B RBCs
Patient 1 4+ 0 NT 3+ 0 1+ 4+
Patient 2 4+ 0 NT 3+ 0 1+ 4+
RBCs = red blood cells; NT = not tested.
80 IMMUNOHEMATOLOGY, Volume 33, Number 2, 2017
G.M. Meny
O screening RBCs. Thus, the final ABO interpretation for 
patient 1 is consistent with an “A subgroup (probable A2) with 
anti-A1.” Note that there were no room temperature–reactive 
RBC alloantibodies present; thus, random group A1, A2, and B 
RBCs were used to perform the reverse typing.
Anti-A1 is considered clinically significant if reactivity is 
observed at 37°C. If reactivity is observed at 37°C, group O 
or A2 RBCs can be transfused to A2 individuals, and group O, 
A2, or A2B RBCs can be transfused to A2B individuals.5 Some 
transfusion services issue only group O RBCs to patients 
with anti-A1 to avoid an incompatible crossmatch or to avoid 
screening units.
The RBCs of patient 2 also demonstrated no agglutination 
with Dolichos biflorus, although the plasma of patient 2 weakly 
agglutinated two examples of A1 RBCs and one example of A2 
RBCs. In addition, screening cell 1 was positive at immediate 
spin and negative at the indirect antiglobulin test. The antibody 
detection test was interpreted as “positive”, and an antibody 
panel detected an anti-M reactive at immediate spin and room 
temperature. ABO reverse testing was repeated with two 
examples each of M– A1, A2, and B RBCs, revealing negative 
results with both group A1 and A2 RBCs and 4+ reactivity 
with group B RBCs. Thus, the final ABO interpretation is 
consistent with “group A (with anti-M).” Note that although 
this individual is also an A subgroup, anti-A1 is not present.
For patients with anti-M, crossmatch-compatible RBCs 
can be transfused when reactivity is observed at 37ºC.18 
Some transfusion services issue M– RBCs in scenarios such 
as that of patient 2 to avoid an incompatible immediate spin 
crossmatch.
Patient 3
Patient 3 was a 26-year-old woman who presented to 
the emergency department with chills and fever (38ºC) and 
a petechial rash noted on her extremities. A complete blood 
count and type and screen were ordered. Initial type and screen 
results noted mixed-field positive agglutination with patient 
RBCs and reagent anti-B on forward type and 1+ agglutination 
with patient plasma and reagent B RBCs on reverse type. The 
same results were obtained upon repeat testing (Table 4).
This patient could have been considered a B subgroup. 
Additional history, however, revealed that the patient was 
post–stem cell transplantation (patient’s native ABO group 
was group A and donor was group B), and the patient received 
multiple RBC and platelet transfusions. The historical 
information was also consistent with the patient’s presentation 
of a potential septic episode, which is a known complication in 
a stem cell transplant patient.
Blood component selection for patients post–stem cell 
transplant is standardized to provide optimum conditions 
for erythropoietic progenitor engraftment.19 This patient 
most likely received group O RBCs and group AB platelets or 
plasma, which also could have contributed to the unusual ABO 
testing results.
Discussion
Serologic methods and information available within 
many hospital-based transfusion service laboratories can be 
used in resolving most ABO discrepancies. Discrepancies can 
be categorized into those involving the forward (RBC) type 
or the reverse (plasma) type. This arbitrary categorization 
helps to focus the search for a cause of the discrepancy. Yudin 
and Heddle20 devised a question-based approach to resolving 
discrepancies in a transfusion service laboratory. Although 
their publication20 focuses on serologic issues involved in 
discrepancies, several of the 13 questions listed in their 
investigative approach are useful and should be part of any 
ABO discrepancy investigation (e.g., What is the patient’s 
diagnosis? What is the transfusion history?).
Unfortunately, ABO discrepancies persist secondary to 
technical issues, especially sample misidentification (wrong 
blood in tube [WBIT]).21,22 Suspected WBIT requires prompt 
investigation per institution protocol because other laboratory 
samples may be involved. Appropriate supervisory staff should 
be notified as soon as technical difficulties are suspected. 
Medical director notification is also imperative because plans 
can be developed regarding transfusion needs, if necessary, 
especially if transfusion is emergent. Medical directors can 
also be of assistance in working with the laboratory and clinical 
staff and patients to provide updates if blood component delays 
or additional sample requests will be forthcoming.
Molecular methods are another tool that may be of use in 
resolving ABO discrepancies. Molecular methods are routinely 
being implemented for use in resolving, for example, Rh system 
discrepancies,23 yet clinical information is not yet available to 
make recommendations regarding widespread use of ABO 
genotyping for initial discrepancy resolution.24 Infrequent 
causes of discrepancies where molecular methods can be 
useful in resolving an ABO discrepancy include suspected 
chimerism. These individuals frequently demonstrate mixed-
Table 4. Initial test results, patient 3
Anti-A Anti-B Anti-A,B Anti-D Rh Control A1 RBCs B RBCs
Patient 3 0 1+mf 1+mf 3+ 0 0 1+
RBCs = red blood cells; mf = mixed field.
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field RBC reactivity. Chimerism can occur either from the 
fusion of more than one zygote (dispermic chimerism), when 
hematopoietic stem cells are shared, such as between twins 
in utero when placental blood vessels form anastomoses (twin 
chimerism), or post–stem cell transplant.25 If molecular testing 
is performed for ABO discrepancy resolution, care must be 
taken to understand the limitations of the test system used 
as well as factors leading to potential genotype/phenotype 
discrepancies.10
References
 1. Reid ME, Shine I. In the beginning was the ABC. In: The 
discovery and significance of the blood groups. Cambridge, 
MA: SBB Books, 2012:3–10.
 2. Daniels G. ABO, H, and Lewis Systems. In: Human blood 
groups. 3rd ed. West Sussex, UK: Wiley-Blackwell, 2013: 
11–95.
 3. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. Method 
2-4. Initial investigation of ABO grouping discrepancies 
procedure. In: Technical manual. 18th ed. Bethesda, MD: 
AABB, 2014.
 4. Unni N, Peddinghaus M, Tormey CA, Stack G. Record 
fragmentation due to transfusion at multiple healthcare 
facilities: a risk factor for delayed hemolytic transfusion 
reactions. Transfusion 2014;54:98–103.
 5. Cooling L. ABO, H, and Lewis blood groups and structurally 
related antigens. In: Fung MK, Grossman BJ, Hillyer CD, 
Westhoff CM, eds. Technical manual. 18th ed. Bethesda, MD: 
AABB, 2014:291–315.
 6. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. 
Method 2-5. Detecting weak A and B antigens and antibodies 
by cold temperature enhancement. In: Technical manual. 18th 
ed. Bethesda, MD: AABB, 2014.
 7. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. Method 
2-6. Confirming weak A and B antigens using enzyme-treated 
red cells. In: Technical manual. 18th ed. Bethesda, MD: AABB, 
2014.
 8. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. 
Method 2-7. Confirming Weak A or B subgroup by adsorption 
and elution. In: Technical manual. 18th ed. Bethesda, MD: 
AABB, 2014.
 9. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. 
Method 2-8. Testing saliva for A, B, H, Lea and Leb antigens. 
In: Technical manual. 18th ed. Bethesda, MD: AABB, 2014.
 10. Yazer MH, Hosseini-Maaf B, Olsson ML. Blood grouping 
discrepancies between ABO genotype and phenotype caused 
by O alleles. Curr Opin Hematol 2008;15:618–24.
 11. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. 
Method 2-19. Using gentle heat elution to test red cells with a 
positive DAT. In: Technical manual. 18th ed. Bethesda, MD: 
AABB, 2014.
 12. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. 
Method 2-22. Separating transfused from autologous red 
cells by simple centrifugation. In: Technical manual. 18th ed. 
Bethesda, MD: AABB, 2014.
 13. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. 
Method 2-23. Separating transfused from autologous red cells 
in patients with hemoglobin S disease. In: Technical manual. 
18th ed. Bethesda, MD: AABB, 2014.
 14. Storry JR, Olsson ML. The ABO blood group system revisited: 
A review and update. Immunohematology 2009;25:48–59.
 15. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. 
Method 2-9. Confirming anti-A1 in an A2 or weak A subgroup. 
In: Technical manual. 18th ed. Bethesda, MD: AABB, 2014.
 16. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. Method 
2-10. Resolving ABO discrepancies caused by unexpected 
alloantibodies. In: Technical manual. 18th ed. Bethesda, MD: 
AABB, 2014.
 17. Yuan S, Fang A, Davis R, Siplon CJ, Goldfinger D. Immunoglobin 
M red blood cell antibodies are frequently removed by rabbit 
erythrocyte stroma. Transfusion 2010;50:1139–43.
 18. Reid ME. MNS blood group system: a review. Immuno-
hematology 2009;25:95–101.
 19. Daniel-Johnson J, Schwartz J. How do I approach ABO-
incompatible hematopoietic progenitor cell transplantation? 
Transfusion 2011;51:1143–9.
 20. Yudin J, Heddle NM. A 13-question approach to resolving 
serological discrepancies in the transfusion medicine 
laboratory. Lab Med 2014:45:193–206.
 21. Bolton-Maggs PH. SHOT conference report 2016: serious 
hazards of transfusion: human factors continue to cause most 
transfusion-related incidents. Transfus Med 2016;26:401–5.
 22. Ferrera-Tourenc V, Lassale B, Chiaroni J, Deltori I. Unreliable 
patient identification warrants ABO typing at admission to 
check existing records before transfusion. Transfus Clin Biol 
2015;22:66–70.
 23. Sandler SG, Flegel WA, Westhoff CM, et al. It’s time to phase 
in RHD genotyping for patients with a serologic weak D 
phenotype. Transfusion 2015;55:680–9.
 24. Flegel WA. ABO genotyping: the quest for clinical application. 
Blood Transfus 2013;11:6–9.
 25. Lomas-Francis C. Blood group genetics. In: Fung MK, 
Grossman BJ, Hillyer CD, Westhoff CM, eds. Technical 
manual. 18th ed. Bethesda, MD: AABB, 2014:278.
Geralyn M. Meny, MD, MS, Physician Consultant, Grifols Diagnos-
tics, 3031 Panzano Place, San Antonio, TX 78258, Geralyn.Meny@
external.grifols.com.
